IGF2BP2 binds to METTL14 m6A‐modified TGFB2 mRNA and upregulates TGFB2 expression, resulting in enhanced gemcitabine resistance in pancreatic cancer. Here, METTL14 is linked to familial pancreatic carcinoma.